were transfected for 24 h after plating with 50 nM, 25 nM, 15 nM, or 5 nM final concentration of either KLF5 or control siRNA using FuGENE HD transfection reagent (Roche Diagnostics, Tokyo, Japan) at 80% confluence on a 6-well culture plate. The efficacy of gene silencing of KLF5 was determined by reverse transcriptase-PCR using a primer set specific for KLF5, and 25 nM of control siRNA and KLF5 siRNA were chosen, respectively. Cells were simultaneously treated with TNF-a or carrier.
The experiments were classified into 4 groups including (1) a control group with control siRNA, (2) an experimental group with KLF5 siRNA, (3) an experimental group with 10 ng/ml TNF-a and control siRNA, and (4) an experimental group with 10 ng/ml TNF-a and KLF5 siRNA.
Isolation of Total RNA and Synthesis of cDNA HUVECs were washed by phosphate-buffered saline (PBS), and total RNA was isolated from HUVECs using TRIzol TM reagent (Invitrogen, Japan). Briefly, after addition of chloroform to HUVECs, the samples were mixed well, and were centrifuged to separate the aqueous and chloroform phases. Total RNA was recovered from the aqueous phase by means of isopropyl alcohol precipitation, and was suspended in diethylpyrocarbonate (DEPC)-treated water (Invitrogen, Japan). We measured the concentrations of RNA extracted from HUVECs, by measuring the optical density at 260 nm with a Nanodrop Spectrophotometor (Scrum, Tokyo, Japan). The purity of RNA in the extracts was determined by calculating the ratio of optical density at 260 nm and 280 nm. Then, 4 mg of pure total RNA was used for cDNA synthesis using SuperScript II TM Reverse Transcriptase (Invitrogen, Japan). Briefly, total RNA was mixed with Oligo (dT) primers (Invitrogen, Japan) and then was denatured by heating at 70°C for 10 min. Reverse transcription was carried out by adding 2 ml SuperScript II TM , 1 ml of 0.1 M DTT (Invitrogen, Japan) and 4 ml of 5-fold diluted standard buffer (Invitrogen, Japan), followed by incubation of the sample at 42°C for 55 min and 70°C for 15 min. The resulting cDNA produced was stored at Ϫ20°C.
Quantification of RNA Expression by Real Time PCR Real time polymerase chain reaction (RT-PCR) was carried out in the iCycler ® (Bio Rad Laboratories Japan, Tokyo) using DYNAmo TM SYBR Green qPCR kit (Bio Rad Laboratories, Japan). PCR reactions were performed in 96-well multiplates TM (Bio Rad Laboratories, Japan). The reaction mixture consisted of 10 ml of 2ϫDYNAmo TM , 0.5 ml of each forward and reverse primers (10 mmol/l), 4 ml H 2 O and 5 ml cDNA template. Primers for MCP-1 were designed according to the Primer 3 program (ver.0.4.0) (http:// frodo.wi.mit.edu/primer3/input.htm). The gene-specific forward and reverse primer sequences are: 5Ј-GTAACC-CGTTGAACCCCATT-3Ј and 3Ј-CCATCCAATCGGTAG-TAGCG-5Ј for 18 s; 5Ј-AGAGGAGGCAATACAGTGG-3Ј and 3Ј-TGGAGAGCCTTAAGACACAG-5Ј for SMemb; 5Ј-TCCTCTGCTGGTTCCTGACT-3Ј and 3Ј-CAGAAACTC-CACCCCTGTGT-5Ј for ET-1; 5Ј-TCTGTGCCTGCTGCT-CATAG-3Ј and 3Ј-TGGAATCCTGAACCCACTTC-5Ј for MCP-1.
The following PCR programs was performed on the iCycler ® : an initial denaturation at 95°C for 10 min to activate DNA polymerase, followed by a 40-cycle program consisting of heating at 20°C/s to 95°C with 10 s hold, cooling at 56°C for 20 s for annealing and heating at 20°C/s to 72°C with 30 s hold for extension. The annealing of ET-1 was carried out at 58°C.
Fluorescent intensity of products was measured at 80°C after the extension phase. PCR was immediately followed by a melting curve analysis to determine the melting point of the double stranded PCR product produced. Each mRNA level was quantified using the standard curve method. Standard curves were constructed using serially diluted standard template. Ct value was used to compute mRNA levels from the standard curve. Each mRNA level was normalized using the ratio to 18S ribosomal RNA, to account for differences in reverse transcription efficiencies and amount of cDNA in reaction mixtures.
Western Immunoblotting After transfection, HUVECs (1ϫ10 6 cells) were incubated at 37°C for 24 h. Then, 1 ml per well of supernatant was collected. The supernatant was centrifuged at 15000 rpm (20000ϫg) for 15 min, and then kept at Ϫ20°C until subsequent use in the Quantikine kit. Cells in each dish were rinsed twice with chilled PBS and were lysed with solution composed of RIPA Lysis Buffer Kit (composed of 10 mM Tris-Cl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride, 10% glycerol, 2 mM sodium orthovanadate, 10 mM sodium fluoride, 20 mM sodium pyrophosphate, 25 mM b-glycerophosphate, 1% Triton X-100, and protease inhibitors) (Santa Cruz Biotechnology, CA, U.S.A.). Whole cell extracts were centrifuged at 10000 rpm (9100ϫg) for 10 min to remove the insoluble materials. Total protein concentration in the supernatant was determined using the Nanodrop ND-1000 Spectrophotometer (Scrum, Tokyo, Japan). Namely, the extracts containing 50-100 mg proteins and the equal volume of 2ϫTris-Glycine SDS Sample Buffer (Invitrogen, Japan) were heated to 100°C for 5 min and underwent SDS-PAGE electrophoresis. The proteins were transferred to PVDF membranes using XCell II SureLock Mini-Cell system (Invitrogen). The membranes were blocked with 5% non-fat milk prior to immunoblotting analysis reacted with anti-human SMemb antibody (Yamasa Corp., Tokyo, Japan) diluted 1 : 6000 in Can-Get Signal Immunoreaction Enhancer Solution (Toyobo, Osaka, Japan) as the primary antibody, followed by anti-mouse IgG conjugated with horseradish peroxidase-linked whole antibody from sheep (GE Healthcare, U.K.) diluted 1 : 200000 for secondary antibody. Finally, the blots were visualized using the enhanced chemiluminescence system (ECL Advanced, GE Healthcare). Densitometric analyses were performed using Scion Image (Scion Corp., Frederick, MD, U.S.A.).
The Quantification of the MCP-1 Expression Level by the ELISA The Quantikine Human MCP-1 Immunoassay kit (R&D Systems, Minneapolis, MN, U.S.A.) was used to measure immunoreactive levels of MCP-1 in the conditioned supernatant. This assay used the anti-human MCP-1 antibody and polyclonal secondary antibody and was quantified by the sandwich method. We measured the MCP-1 level according to instructions provided by the manufacturer. We established the calibration curve from the actual values of the standard MCP-1 solution which we measured. MCP-1 levels in conditioned media were calculated from the standard curve and compared after correction with the cell numbers in each well. Data are shown as meanϮS.E.
Statistical Analysis
The data were expressed as meansϮS.E. and were analyzed by ANOVA followed by Scheffe's post-hoc test using Statcel-2 software (OMS Publishing Inc., Saitama, Japan). A p-value less than 0.05 was considered to indicate a statistically significant difference.
RESULTS
The proliferation of HUVECs showed linear growth until 24 h in control siRNA and 25 nM KLF5 siRNA, which did not show any significant difference between these groups. However, cell viability was relatively decreased by KLF5 siRNA at a 50 nM final concentration compared to 25 nM (data not shown). These results indicate that 25 nM of KLF5 siRNA does not exert cytotoxic effects on HUVECs.
On the other hand, the KLF5 mRNA level was reduced extensively in HUVECs when the cells were treated with 25 nM KLF5 siRNA for 24 h (60% reduction of the control cells with control siRNA) (Fig. 1A) , suggesting that KLF5 siRNA, which was extracellularily transfected, was incorporated into HUVECs and inhibited the expression of KLF5 mRNA in the cells. SMemb protein expression was also decreased by KLF5 siRNA in a dose-dependent manner as shown in Fig.  1B . Depending on these data, we chose 25 nM of KLF5 siRNA for the following experiments.
The level of SMemb in HUVECs was significantly decreased when the cells were treated with KLF5 siRNA (1st and 2nd columns in Fig. 2, middle) . It decreased further when the cells were treated with TNF-a and control siRNA or with TNF-a and KLF5 siRNA (3rd and 4th columns in Fig. 2, middle) . The changes in SMemb in HUVECs were different from those in MCP-1 and ET-1. When HUVECs were treated with KLF5 siRNA, the levels of MCP-1 was not altered (1st and 2nd columns in Fig. 2, left) . The levels of MCP-1 in HUVECs increased 10 times, when the cells were treated with TNF-a. This augmentation was decreased in the presence of KLF5 siRNA (3rd and 4th columns in Fig. 2,  left) . The level of ET-1 was not changed by KLF5 siRNA compared to control siRNA (1st and 2nd columns in Fig. 2,  right) . It was significantly increased in KLF5 siRNA when treated with TNF-a (2nd and 4th columns in Fig. 2, right) . There was no significant increase between control siRNA and control siRNA treated with TNF-a (1st and 3rd columns in Fig. 2, right) .
Since the expression of MCP-1 mRNA was extensively augmented in HUVECs with TNF-a and the augmentation was decreased by KLF5 siRNA, we evaluated the concentrations of MCP-1 protein secreted from HUVECs treated with The mRNA expressions were evaluated 24 h after the incubation of the cells with (1) control siRNA, (2) KLF5 siRNA, (3) 10 ng/ml TNF-a and control siRNA, and (4) 10 ng/ml TNF-a and KLF5 siRNA. Comparison of the mRNA expression of MCP-1 (left), SMemb (middle) and ET-1 (right). Outlined columns represent result of the treatment with control siRNA and shadowed columns for KLF5 siRNA. Data are shown as an arbitrary ratio to 18S rRNA and meanϮS.E. (nϭ4, * represents significant difference as pϽ0.05, † represents significant difference as pϽ0.01).
Fig. 3. Comparison of MCP-1 Protein Expression in Supernatant of Conditioned Media
The protein levels of MCP-1 in the conditioned media of HUVECs ware evaluated 24 h after the incubation of the cells with (1) control siRNA, (2) KLF5 siRNA, (3) TNF-a and KLF5 siRNA. As shown in Fig. 3 , when HUVECs were treated with TNF-a, the level of MCP-1 protein in the conditioned medium was extensively increased. However, it was attenuated significantly when the cells were treated with TNF-a and KLF5 siRNA. These MCP-1 protein changes caused by KLF5 siRNA showed a decrease similar to the MCP-1 mRNA changes in Fig. 2 .
DISCUSSION
We set out to determine the role of KLF5 in the regulation of inflammation through MCP-1. MCP-1 plays a pivotal role in the progression of atherosclerosis, contributing to the process that monocytes migrate to intima in the early stage of the atherosclerotic formation.
6,7) MCP-1 expressed only at low levels in normal vasculature including in endothelial cells and smooth muscle cells. However, the MCP-1 level increases in endothelial cells when they receive a variety of stresses such as consecutive hyperglycemic conditions in diabetic patients [8] [9] [10] and TNF-a. 17, [20] [21] [22] Moreover, it has been shown that CC chemokine receptor (CCR2), the specific receptor of MCP-1, appeared in these cells, and plays essential roles in angiogenesis and proliferation of the vascular wall cells. MCP-1 also accelerates the expression of various cytokines to promote inflammation and cellular proliferation. 14) Cytokines then further amplify cellular MCP-1 production.
Because MCP-1 is strongly expressed in macrophage-rich areas of human atherosclerotic lesions, 3) the regulation of MCP-1 provides a beneficial strategy to prevent atherosclerosis.
There have been several studies reported on MCP-1 and the prevention of atherosclerosis such as the effectiveness of CCR2-knock down 4, 5) and MCP-1 deficiency in the hypercholesterolemic mice. 7) Our data showed that the augmentation of MCP-1 in HUVECs by TNF-a was decreased by the inhibition of KLF5. This phenomenon is a new finding regarding KLF5, which may influence TNF-a induced MCP-1 production in endothelial cells.
Our experiments indicated that TNF-a caused increases in MCP-1 (Fig. 2, left) but not SMemb (Fig. 2, middle) nor ET-1 (Fig. 2, right) . We also found that an inhibition of KLF5 led to the downregulation of elevated MCP-1 by TNF-a, but not of other parameters, in HUVECs. As shown in Fig. 3 , comparison of MCP-1 protein expression in conditioned media was compatible with mRNA levels in Fig. 2 . These results may suggest that both ET-1 and SMemb are regulated by different pathways from the TNF-a signal.
Previous reports revealed that SMemb is regulated by the transcriptional factor KLF5, 23) and both are also reinduced in artherosclerotic lesions. 19, 24, 25) KLF5 is also important in vascular remodeling via angiotensin II in vascular smooth muscle cells. 26, 27) We reported that the SMemb level increased in HUVECs cultured in a high concentration of glucose. 28) SMemb then may be related to the dedifferentiation and vascular remodeling in diabetic atherosclerosis. In this study, we have first shown that KLF5 inhibition reduces SMemb expression not only in smooth muscle cells but also in endothelial cells. However, the result on SMemb expression by TNFa-stimulation suggested that SMemb in endothelium is possibly regulated not only by KLF5 but also by other pathways related to TNF-a which trigger the death pathways in normal human endothelial cells, 29, 30) although lipopolysaccharide or TNF-a may increase KLF5 in the intestinal epithelial cells. 18) KLF5 inhibition may have an additive effect to reduce SMemb expression with TNF-a. Further investigation is necessary to elucidate the unknown cascade regulating SMemb through TNF-a.
Though the interaction between KLF5 and MCP-1 in HUVECs is still controversied, new transcriptional research findings suggested that NF-kB and AP-1 are related to the transactivation of the MCP-1 promoter. 31 ) KLF5 binds to NF-kB and enhances the action in HeLa cells. 32) Moreover, NF-kB inhibitor reduced MCP-1 production in cocultured media where NF-kB activity was upregulated. 33) These results suggest that KLF5 may be related to MCP-1 and NF-kB. Also, Yang and Chanchevalap reported that TNF-a enhanced by lipopolysaccaride was attenuated by KLF5 siRNA in mouse intesitinal epithelial cells, 18) suggesting that KLF5 regulates mRNA of p65 and p50 NF-kB subunits in the cells, and that KLF5 siRNA reduced the binding activity of NF-kB to the specific binding site of target genes.
Our results suggest a hypothetical cascade in which KLF5 regulates the binding activity to NF-kB and KLF5 siRNA reduces the MCP-1 transcription.
It is clear that the inhibition of MCP-1 would contribute to improve insulin resistance and inhibit arterial sclerosis. The elucidation of the cascade of KLF5 will be useful for the treatment of arteriosclerosis. Our data suggest that the suppression of KLF5 could act beneficially against TNF-a-induced MCP-1 expression.
In conclusion, we present a novel KLF5 role in vasculature to regulate inflammation via MCP-1 in vitro study. Clinically, inhibition of KLF5 could prevent monocyte accumulation in TNF-a-rich obese patients.
